Speciogynine & the Opioid System
Summary: In the same head-to-head panels where mitragynine shows MOR activity, speciogynine does not behave as a MOR agonist; opioid-like effects of kratom are therefore unlikely to be driven by speciogynine.
Key points:
Across μ/κ/δ opioid assays, speciogynine lacks mitragynine-like agonism.
Practical takeaway for readers: lumping “all kratom alkaloids” as opioids is inaccurate; receptor fingerprints differ markedly by molecule.
